DeepMed Research

JYB-1904

Generic Name: JYB-1904

Clinical Trials

Trial of JYB1904 in Chronic Spontaneous Urticaria.

Phase 2

Recruiting

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: JYB1904
Drug: Omalizumab

First Posted Date: 2024-07-19

Last Posted Date: 2024-11-28

Lead Sponsor: Jemincare

Target Recruit Count: 135

Registration Number: NCT06509334

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Trial of JYB1904 in Allergic Asthma

Phase 2

Active, not recruiting

Conditions: Allergic Asthma

Interventions: Drug: JYB1904
Drug: Omalizumab

First Posted Date: 2024-06-03

Last Posted Date: 2025-05-07

Lead Sponsor: Jemincare

Target Recruit Count: 69

Registration Number: NCT06438757

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JYB1904
Drug: Omalizumab
Drug: JYB1904 Placebo

First Posted Date: 2022-07-08

Last Posted Date: 2023-06-27

Lead Sponsor: Jemincare

Target Recruit Count: 56

Registration Number: NCT05449535

Locations: 🇨🇳
Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang, China

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy